Literature DB >> 34280013

Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an In Vivo Microdialysis Study.

M Edlinger-Stanger1, V Al Jalali2, M Andreas3, W Jäger4, M Böhmdorfer4, M Zeitlinger2, D Hutschala1.   

Abstract

Ceftaroline fosamil, a fifth-generation cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA), is currently approved for the treatment of pneumonia and complicated skin and soft tissue infections. However, pharmacokinetics data on free lung tissue concentrations in critical patient populations are lacking. The aim of this study was to evaluate the pharmacokinetics of the high-dose regimen of ceftaroline in plasma and lung tissue in cardiac surgery patients during intermittent and continuous administration. Nine patients undergoing elective cardiac surgery on cardiopulmonary bypass were included in this study and randomly assigned to intermittent or continuous administration. Eighteen hundred milligrams of ceftaroline fosamil was administered intravenously as either 600 mg over 2 h every 8 h (q8h) (intermittent group) or 600 mg over 2 h (loading dose) plus 1,200 mg over 22 h (continuous group). Interstitial lung tissue concentrations were measured by in vivo microdialysis. Relevant pharmacokinetics parameters were calculated for each group. Plasma exposure levels during intermittent and continuous administration were comparable to those of previously published studies and did not differ significantly between the two groups. In vivo microdialysis demonstrated reliable and adequate penetration of ceftaroline into lung tissue during intermittent and continuous administration. The steady-state area under the concentration-time curve from 0 to 8 h (AUCss 0-8) and the ratio of AUCSS 0-8 in lung tissue and AUC in plasma (AUClung/plasma) were descriptively higher in the continuous group. Continuous administration of ceftaroline fosamil achieved a significantly higher proportion of time for which the free drug concentration remained above 4 times the minimal inhibitory concentration (MIC) during the dosing interval (% fT>4xMIC) than intermittent administration for pathogens with a MIC of 1 mg/liter. Ceftaroline showed adequate penetration into interstitial lung tissue of critically ill patients undergoing major cardiothoracic surgery, supporting its use for pneumonia caused by susceptible pathogens.

Entities:  

Keywords:  cardiac surgery; ceftaroline; microdialysis; pharmacokinetics; pneumonia

Mesh:

Substances:

Year:  2021        PMID: 34280013      PMCID: PMC8448148          DOI: 10.1128/AAC.00679-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  63 in total

Review 1.  Lung microdialysis--a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review).

Authors:  Markus Zeitlinger; Markus Müller; Christian Joukhadar
Journal:  AAPS J       Date:  2005-10-22       Impact factor: 4.009

2.  Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.

Authors:  Mohd H Abdul-Aziz; Helmi Sulaiman; Mohd-Basri Mat-Nor; Vineya Rai; Kang K Wong; Mohd S Hasan; Azrin N Abd Rahman; Janattul A Jamal; Steven C Wallis; Jeffrey Lipman; Christine E Staatz; Jason A Roberts
Journal:  Intensive Care Med       Date:  2016-01-11       Impact factor: 17.440

3.  FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

Authors:  Donald E Low; Thomas M File; Paul B Eckburg; George H Talbot; H David Friedland; Jon Lee; Lily Llorens; Ian A Critchley; Dirk A Thye
Journal:  J Antimicrob Chemother       Date:  2011-04       Impact factor: 5.790

4.  Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.

Authors:  Jason A Roberts; Marta Ulldemolins; Michael S Roberts; Brett McWhinney; Jacobus Ungerer; David L Paterson; Jeffrey Lipman
Journal:  Int J Antimicrob Agents       Date:  2010-08-03       Impact factor: 5.283

5.  International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT).

Authors:  Antoni Torres; Michael S Niederman; Jean Chastre; Santiago Ewig; Patricia Fernandez-Vandellos; Hakan Hanberger; Marin Kollef; Gianluigi Li Bassi; Carlos M Luna; Ignacio Martin-Loeches; J Artur Paiva; Robert C Read; David Rigau; Jean François Timsit; Tobias Welte; Richard Wunderink
Journal:  Eur Respir J       Date:  2017-09-10       Impact factor: 16.671

Review 6.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

7.  A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.

Authors:  Matthew Dryden; Yingyuan Zhang; David Wilson; Joseph P Iaconis; Jesus Gonzalez
Journal:  J Antimicrob Chemother       Date:  2016-09-01       Impact factor: 5.790

Review 8.  Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review.

Authors:  Reese A Cosimi; Nahal Beik; David W Kubiak; Jennifer A Johnson
Journal:  Open Forum Infect Dis       Date:  2017-05-02       Impact factor: 3.835

9.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

10.  Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis.

Authors:  Giovanni Sotgiu; Stefano Aliberti; Andrea Gramegna; Marco Mantero; Marta Di Pasquale; Federica Trogu; Laura Saderi; Francesco Blasi
Journal:  Respir Res       Date:  2018-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.